| Name | Title | Contact Details |
|---|
Mold Law Groups litigation platform is a culmination of over 15 years of in-depth research by environmentalists, epidemiologists, toxicologists, medical professionals, Neurotoxicologists, Neuropsychologists, and law firms. Our proven methodology, for the first time, provides litigators the ability to couple the human pathogens in an environment to the direct causation of disease within the human body. The development of this cutting-edge science required an understanding of many different scientific disciplines and medical philosophies to provide a unique and new model for mold litigation. This platform is designed to defend or prosecute property and medical damages caused by mold and microbial exposure. Using precision based DNA-PCR sequencing, bacteria culturing, endotoxin testing, (1—>3)β-D beta glucan and other advanced environmental and medical testing, we leverage cutting edge technology and advanced mold litigation techniques to provide our clients with unparalleled and detailed services found nowhere else in our industry. Mold Law Group offers expert witnesses, consulting services, medical resources, legal resources, and environmental resources. We offer these services nationally and internationally. Mold Law Group is the absolute gold standard when it comes to mold litigation consulting.
Tremont Strategies Group is a full service government affairs consulting firm offering a wide range of practices and committed to offering the highest quality service to its clients. Our firm specializes in executing complex, multi-faceted campaigns by utilizing a comprehensive approach to engage stakeholders, policymakers and the general public in order to educate and advocate for our client`s position. With decades of experience in the public and private sectors, we offer in-depth analysis on policy matters and proposals before state and federal government. Our team provides the expertise and entrepreneurial creativity needed to build successful comprehensive public affairs strategies.
BHS Corrugated – leading provider of solutions for the corrugated industry BHS Corrugated is the leading provider of solutions for the corrugated industry with 3,000 employees at headquarters in Weiherhammer, Germany as well as in more than 20 countries. As Lifecycle Partner, BHS Corrugated is consistently strong across the entire product and service range: from development and production, to installation and maintenance, to a variety of innovative Lifecycle Service solutions in the areas of corrugating rolls, individual machines, complete corrugators, industry 4.0, logistics and soon to come digital print in- and outside the corrugator. Significant aspects of digitalization, primarily regarding the optimization of process parameters and increasing degrees of automation and production efficiency, have been central issues of BHS Corrugated for many years. To meet the requirements of its customers as precisely as possible and to be always state-of-the-art, BHS Corrugated reinvests close to 5 percent of its turnover in research and development. In addition to its core business, BHS Corrugated supports different social projects, for example the familys own foundation "Angels for Children" or the "Lars und Christian Engel Stiftung (LUCE Trust)", which supports technological and economic development in the region. Contact: BHS Corrugated Maschinen- und Anlagenbau GmbH Paul-Engel-Str. 1 92729 Weiherhammer info@bhs-world.com Tel. +49 9605 919 0 bhs-world.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.